Targeting FLVCR1-enabled choline use in a aggressive AML subtype
Official title: Exploiting FLVCR1-mediated choline transport in acute myeloid leukemia
Funded at Seattle Children's Hospital · NIH-11427960 · Data updated 2026-11-12
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 10, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $597,193 |
| NIH project number | 1R01CA316048-01 |
| Project ID | NIH-11427960 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with CBFA2T3-GLIS2 (CG) AML or related aggressive AML subtypes may be eligible for future trials.
✕Less likely to help
Patients with AML subtypes not dependent on FLVCR1-mediated choline uptake may not benefit.
What this research studies
This project focuses on acute myeloid leukemia driven by a CBFA2T3-GLIS2 fusion, a subgroup with poor survival. Researchers will use genome-scale CRISPR screens to identify essential pathways and focus on FLVCR1, a transporter that brings in choline for cell membranes. By studying CG-AML and normal blood formation, they will uncover how FLVCR1 supports cancer cells and whether other AML types rely on it too. The work could reveal new therapeutic angles that specifically target cancer cells while sparing normal blood cells.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that cut off a critical nutrient supply for dangerous AML cells.
How similar studies have gone: CRISPR-based screens have been used to identify essential cancer dependencies, with several showing translational potential.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Lin, Shan — Seattle Children's Hospital
- Study coordinator: Lin, Shan
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
-
New drug target pathway to fight acute myeloid leukemia (AML) by disrupting selenium use
A new grant explores how AML cells depend on selenium metabolism and how blocking certain regulators can trigger cancer cell death, with potential benefits for adults with AML.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.